Lyell Immunopharma (LYEL) Asset Writedowns and Impairment (2021 - 2025)

Lyell Immunopharma's Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $1.4 million for Q2 2025.

• In Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $52.7 million (up 13.82% YoY), while the FY2025 annual figure was $1.4 million, down 97.19% from the prior year.
• Asset Writedowns and Impairment came in at $1.4 million for Q2 2025 at Lyell Immunopharma, down from $51.3 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $51.3 million in Q4 2024 to a low of -$5.0 million in Q4 2022.
• A 4-year average of $17.8 million and a median of $5.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 113.74% in 2022 and fell as far as 113.74% in 2022.
• Lyell Immunopharma's Asset Writedowns and Impairment stood at $36.4 million in 2021, then plunged by 113.74% to -$5.0 million in 2022, then surged by 1125.94% to $51.3 million in 2024, then tumbled by 97.27% to $1.4 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.4 million, $51.3 million, and -$5.0 million for Q2 2025, Q4 2024, and Q4 2022 respectively.

Peer Comparison